Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: study protocol for a randomized controlled trial

Table 2 Dose modification

Toxicity (grade)	Dose modification
ANC <1000/mm³	Discontinue the treatment until ANC ≥1500/mm³; resume the treatment with the same dose
Platelets <50,000/mm³	Discontinue the treatment until platelets ≥100,000/mm³; resume the treatment with the same dose
Other toxicities	No dose modification or interruption required
Grades 1 and 2	Discontinue the treatment until returns to baseline; resume the treatment to 200 mg daily
Grades 3 and 4

ISSN: 1745-6215